As China continues to inch ahead of competition in terms of trial initiations, immunology and metabolic disease trials attract sponsor eyes.

As the first half of 2026 draws to a close, experts at Arena International’s OCT East Coast reflect on the key trends shaping the sector.

BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to 12 years with ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) ...

Today, 20 May, marks Clinical Trials Day. Editor Abigail Beaney spoke with CML patient Mel Mann who was one of the first patients to receive Gleevac.

While Vincentage's study will only support approval of the oral GLP-1RA in China, the drug is in a Phase II trial in the US.

Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody aimed at KLK5/7 and IL-13.

Regeneron Pharmaceuticals has reported that its Phase III trial assessing fianlimab and cemiplimab for metastatic melanoma failed to reach statistical significance for the primary endpoint.

If Protara secures approval for TARA-002 in NMIBC, it would become the first drug in its class to get the regulatory greenlight.

MSD said that TroFuse-005 is the first global Phase III trial to demonstrate statistically significant improvement in both OS and PFS compared to chemotherapy for these patients and the first and only ...

As rheumatologists prepare for EULAR 2026, Clinical Trials Arena takes a look at the most promising drugs in late-stage development for PsA.

Ipsen has announced Phase II corabotase data in glabellar lines, reporting sustained duration of effect and consistently high patient satisfaction.

At ASCO 2026, AstraZeneca will release the first results from its first-in-human, open-label Phase I/II trial, PRIMAVERA (NCT06137144).